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artifacts. Since a previous literature review by San Martin-Rodriguez et al. in 2005,
many more studies have examined organizational determinants, yet studies re-
garding systematic factors, such as health care systems, remain scarce.
CONCLUSIONS: Interprofessional collaboration is influenced by systematic, orga-
nizational, and interactional factors. Policies targeting multi-level aspects may be
helpful in enhancing interprofessional collaboration and ultimately improving pa-
tient care. Future studies are needed to examine factors beyond the interactional
level and their relationships with patient outcomes.
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OBJECTIVES: To investigate the characteristics of clinical trials conducted in 5
Asian countries over the past 2 years with a focus on: disease conditions, funding
sources and age groups. METHODS: ClinicalTrials.gov was searched for trials ini-
tiated after January 1, 2010 in the following countries: Indonesia, Korea, Malaysia,
Taiwan and Thailand. The 10 most common conditions and trial sponsors were
ranked and the percentage of trials in adults and children was calculated. These
figures were compared between countries. RESULTS: During the time period, the
following number of trialswere identified (number; trials per 1,000,000 population):
Taiwan (826; 35.6), Korea (1597; 32.7), Thailand (375; 5.4), Malaysia (132; 4.6) and
Indonesia (47; 0.2). The most common trials in all countries were for chronic con-
ditions. Trials on type 2 diabeteswere themost common trials in Taiwan, Thailand,
Malaysia and Indonesia (range: 3-18%), and were the 3rd most common in Korea
(2%). Breast cancer trials were also common in all 5 countries (range: 1-2%) and
non-small cell lung cancer trials were common in 4 countries (range: 1-2%), except
Indonesia. Funding for the trials was predominantly non-industry in Taiwan, Thai-
land and Korea (64%, 61% and 53% respectively), but predominantly industry in
Malaysia and Indonesia (72% and 54% respectively). Over 40% of trials in Taiwan
were sponsored by local medical institutions. Trials in adults alone were the most
common in all countries: Korea (84%),Malaysia (84%), Taiwan (81%), Thailand (74%)
and Indonesia (65%). CONCLUSIONS: The number of trials per 1,000,000 population
was much higher in Taiwan and Korea than in Thailand, Malaysia and Indonesia.
Trials conducted in all these countries, however, show strong similarities in terms
of the conditions studied; although there are some differences (e.g. funding
sources) between the countries that suggest other factors influence clinical trials in
these countries.
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OBJECTIVES: To explore the perceptions of Malaysian community pharmacist to-
wards locally manufactured generic medicines. METHODS: A cross-sectional de-
scriptive study involving entire population (N 270) of practising community phar-
macists in the State of Penang, Malaysia was undertaken using a self-completed
anonymous mail questionnaire. RESULTS: Responses were received from 48 phar-
macists (response rate 17.8%). Majority of the respondents (97.9%) actively dis-
pensed generic medicines in their practice. Only 37.5% of the respondents viewed
locally manufactured generic medicines as equal in quality compared to the im-
ported generics from international manufacturers. Approximately 60% of the re-
spondents, however, agreed that domestic generics are equal in safety and efficacy
as the imported generic medicines. About half of the respondents (47.9%) believed
that imported generic products need to pass more stringent approval process.
Majority of the respondents (68.8%) urged that theMalaysian regulatory authorities
should convince pharmacists about the quality of domestic generic medicines.
CONCLUSIONS: The Malaysian pharmacists have lack of confidence with the ge-
neric medicines produced by local pharmaceutical companies.
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OBJECTIVES: Lung cancer (LC), the most common cancer in Asia, accounts for
nearly 14.3% of all new cancer incidences and 18.5% of all cancer-related deaths.
Limited treatment options are available in the advanced stages of LC indicating a
high unmet need. The objective of this study was to conduct an assessment of
drugs in development (both off-patent and pipeline) for LC treatment in Asia.
METHODS: Clinicaltrials.gov was searched in February 2012 for randomized con-
trolled trials (Phase II, III, and IV) investigating pharmacologic interventions for LC
in Asia. RESULTS: In total, 137 clinical trials (planned, ongoing, and completed
trials) were identified. Of these, approximately 42% trials have sites only in Asia;
China and/or Taiwan being the major investigational sites. Among these trials, 44
drugs were found to be in pipeline for the treatment of LC. Major progress was
observed in the area of molecular targeted therapies either as monotherapy or in
combinationwith chemotherapy (50%) followed by chemotherapeutic agents (25%)
and immunotherapeutic agents (25%). Majority (59%) of the ongoing phase III trials
are assessing targeted therapies. The key therapeutic classes in assessment in-
clude epidermal growth factor receptor (EGFR)-targeting agents, vascular endothe-
lial growth factor receptor (VEGFR)-targeting agents, protein kinase inhibitors, he-
patocyte growth factor receptor (HGFR) or c-Met inhibitors, and pan-ErbB
inhibitors. Among trials evaluating targeted therapies, EGFR-targeting agents were
being investigated in more than 50% of the trials followed by VEGFR-targeting
agents. CONCLUSIONS: The research focus for the treatment of LC is shifting from
chemotherapies towards the targeted therapies in Asia. Among the targeted ther-
apies, the major focus is on the EGFR-targeting agents.
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OBJECTIVES:Globally, the consideration of subgroup analyses is an emerging topic
in health care evaluation; however, it is unclear towhat extent the consideration of
biomarkers is relevant to Asian health care systems. In particular, the use of bio-
markers is expected to play a large role in cancer treatments, as these are often
expensive and indicated in small populations. The aim of this study was to inves-
tigate how the proportion of cancer trials considering biomarkers in six Asian
countries compared to the USA and the world. METHODS: ClinicalTrials.gov was
searched for all cancer trials that considered the use of biomarkers, by using search
terms such as ‘diagnostic marker’. We assessed the number of trials being carried
out in six Asian countries: Japan, Singapore, Thailand, Malaysia, the Philippines
and Taiwan. The results were compared to all cancer trials conducted in these
countries, in the USA, and globally. RESULTS: Proportions of cancer trials consid-
ering biomarkers differed between the countries assessed, with Taiwan having the
highest percentage of just over 20%,whereasMalaysia andThailandhad the lowest
proportions with 5.2% and 5.4%, respectively. Interestingly, Malaysia and the Phil-
ippines had fewest cancer trials in general, with only 77 and 87 cancer trials having
been conducted in these countries. This compared to 28,414 cancer trials being
conducted worldwide, 3,848 of which (13.5%) considered biomarkers. This propor-
tion was similar in the USA, where 13.1% of cancer trials included some use of
markers. CONCLUSIONS: It is clear that the consideration of biomarkers in cancer
trials is common in the more developed health care markets in Asia such as Sin-
gapore and Taiwan, where proportions of cancer trials taking this into account
were higher than in the USA and globally. Smaller Asianmarkets such asMalaysia,
the Philippines and Thailand appear to lag behind in the trend towards subgroup
analysis.
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OBJECTIVES: To find the hospital mortality andmid term functional improvement
in patients with impaired ventricular function undergoing coronary artery by pass
grafting and identify the risk factors for mortality.METHODS: Retrospective anal-
ysis of preoperative, operative and postoperative variables of patients with im-
paired ventricular function who were operated for isolated first time coronary
artery bypass betweenOctober 2006 toApril 2009.RESULTS:Total 190 patientswith
impaired ventricular function underwent isolated first time coronary artery bypass
grafting during this periodwith amale predominance (82.6%). This constituted 12%
of all coronary artery surgery performed at our institution during this period. Mean
ejection fraction of the group was 25.45.3%. Mean predicted mortality on logistic
Euro scorewas 10.92.7%. Actual in hospitalmortality of the groupwas 4.7%which
is comparable to contemporary published results. Multivariate analysis identified
use of intra aortic balloon pump, non use of internal mammary artery and preop-
erativeNYHA functional class as factors associatedwithmortality.CONCLUSIONS:
Coronary artery bypass grafting can be performed in patients with impaired ven-
tricular function with acceptable hospital mortality and mid term functional im-
provement.
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OBJECTIVES: In the NewChineseMedical Reform, university students are included
into themedical insurance system for urban residents (URMS) from 2010 to resolve
their uninsured status. The current study aimed to evaluate the effect of new
health system from the perspective of the insured students one year after program
implementation. METHODS: Based on the Chinese Customer Satisfaction Index
and review of the literatures, we built a satisfaction evaluation system for URMS of
university students, with one first-level, 7 second-level (Latent variable, xm) and 24
third-level indicators (Explicit variable, yn) to be scored on a five-point Likert-type
scale. After pilot testing and subsequent adjustment, 400 questionnaires were is-
sued to students in 4 universities in NE China. After obtaining the affecting order of
third indexes to their corresponding secondary index through the correlation test,
a Structural Equation Model (SEM) for the satisfaction assessment of URSM was
built basing on the calculated Path coefficient between the xm and yn aftermultiple
linear regressions. Goodness of fit statistics of SEM were used to assess the match
between this model and satisfaction assessment. RESULTS: 393 questionnaires
were returned giving a recovered rate 98.3%. The path coefficients between xm and
yn were: customer trust 1.26, the perceived quality 0.88, customer complaints 0.80,
customer expectations 0.44, public information 0.31, and image of the government
0.29. The satisfaction score of UMRS (29.06 out of 69.75 points) showed very low
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